On March, 14 is awaited Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s earnings report, according to Faxor. Analysts predict $-0.10 EPS, which is $0.12 down or 600.00 % from 2018’s $0.02 EPS. Wall Street now forecasts -33.33 % EPS growth despite Brainstorm Cell Therapeutics Inc. previous quarter’s EPS of $-0.15. BCLI touched $3.9 during the last trading session after $0.005 change.Currently Brainstorm Cell Therapeutics Inc. is downtrending after 25.37% change in last March 3, 2018. BCLI has 50,513 shares volume. BCLI underperformed by 25.37% the S&P 500.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, and others.The firm is valued at $80.76 million. The firm holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd.Last it reported negative earnings. The Company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons.

For more Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) news announced recently go to: Globenewswire.com, Globenewswire.com, Seekingalpha.com, Seekingalpha.com or Globenewswire.com. The titles are as follows: “BrainStorm Issues a Statement to Patients and Shareholders – GlobeNewswire” announced on February 19, 2019, “BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposium – GlobeNewswire” on February 04, 2019, “BrainStorm’s late-stage study of NurOwn in ALS to continue as planned; shares up 4% premarket – Seeking Alpha” with a publish date: August 23, 2018, “BrainStorm Cell Therapeutics ALS Data Not As Promising As Press Releases Indicate – Seeking Alpha” and the last “BrainStorm Granted Additional Patent for NurOwn® in Israel – GlobeNewswire” with publication date: January 22, 2019.